New oncology drugs in the European Union (EU) are assessed under a centralized procedure by the European Medicines Agency (EMA); however, even if a European marketing authorization (MA) has been granted, this does not imply that the product will be available to patients everywhere in the EU [1]. In Italy, new provisions on health care have been introduced through the legislative decree nr. 158/...